--- title: "UK Budget introduces founder tax relief and boosts biotech investment" publisher: "Stockmark.IT" author: "Stockmark.IT Website" published: "2026-10-30T07:42:58+00:00" modified: "2026-10-30T07:42:58+00:00" date: 2026-10-30 canonical: "https://stockmark.it/uk-budget-light-on-life-sciences-but-more-doors-open-for-biotech-start/" category: "Investment" categories: ["Investment", "UK Budget", "UK Government"] image: "https://i0.wp.com/stockmark.it/wp-content/uploads/2026/10/uk-budget-introduces-founder-tax-relief-and-boosts-biotech.png?fit=1536%2C1024&quality=80&ssl=1" format: "news" language: "en-GB" --- # UK Budget introduces founder tax relief and boosts biotech investment **Published:** October 30, 2026 **Author:** Stockmark.IT Website **Categories:** Investment, UK Budget, UK Government **Featured image:** ![UK Budget introduces founder tax relief and boosts biotech investment](https://i0.wp.com/stockmark.it/wp-content/uploads/2026/10/uk-budget-introduces-founder-tax-relief-and-boosts-biotech.png?fit=1536%2C1024&quality=80&ssl=1) --- The UK Autumn Budget has introduced a new tax relief scheme for business founders alongside significant increases in public and private investment for the life sciences sector. While the government noted that the measures were not exclusively targeted at biotechnology, the incentives for early-stage enterprises are expected to support companies seeking to establish a presence in Britain. The central element of the financial package is a framework designed to assist founders of high-growth and innovative firms in scaling their operations within the United Kingdom. The new initiative, designated as Founders Relief, provides eligible founders with a reduced Capital Gains Tax rate of 10 per cent on lifetime gains of up to £10m. This represents a substantial reduction from the standard rate of 18 per cent. To qualify for this benefit, founders must satisfy specific criteria related to scaling, innovation, and business activity. In addition to this relief, the trading allowance for individuals starting a business has been tripled to £3,000. The government stated that it would also enhance venture capital schemes, simplify access to research and development tax reliefs, and facilitate employee share ownership in their respective companies. Industry reactions to the proposals have been mixed. Chris Molloy, chief executive of the BioIndustry Association, acknowledged the broad merit of the relief but argued that the initial inclusion criteria are more applicable to high street businesses than to venture capital-backed biotechs. He indicated that the association would work with members and the Treasury during the upcoming consultation period to ensure the specific needs of biotech founders are understood. Conversely, Gail Vallis, a partner at law firm Gardner Leader, described the move as positive for those taking substantial risks in setting up new companies at the cutting edge of research and development. However, she noted that the scheme may not adequately address the needs of those who have taken similar risks on existing early-stage companies or those who have rescued struggling businesses. Chancellor John Healy announced a £20.4bn boost to the National Wealth Fund and the British Business Bank. The latter serves as a key financing vehicle for small and medium-sized enterprises. Molloy expressed satisfaction with the increased and front-loaded budget for the British Business Bank, which is intended to support funders and companies across biotech and dual-use technologies. The Budget also includes new legislation aimed at reducing non-compete clauses as a barrier for startups and scaling firms to attract talent, with guidance expected to be released in early 2027. The government stated that these steps are designed to help achieve its ambition of making the UK the best place in the world to start, scale, and maintain a business. Among the life science-specific announcements, the Budget outlined a series of public-private investments worth over £1bn, of which only £70m was backed by government grants. Major corporate commitments include Vertex Pharmaceuticals opening a new £300m facility in Oxford, Convatec investing over £500m in a new research and development hub in Manchester over the next decade, and Kindeva allocating £200m to its base in Loughborough. Vallis commented that while the grant funding is welcome, it may be insufficient for companies looking to advance drugs through clinical trials, emphasising the need for further work to attract wider investor participation. The Budget arrives at a time of renewed optimism in the UK biotech sector. A recent report by the BioIndustry Association suggests the UK is on track for its best year since 2021 for biotech venture capital acquisition. Mergers and acquisitions have also seen notable success, with three deals exceeding $1bn involving British biotechs in 2026. The largest of these was the acquisition of Centessa Pharmaceuticals by Eli Lilly for up to $7.8bn in June. Despite this activity, the wait for a biotech listing in the UK continues, reflecting ongoing hesitancy regarding the nation’s wider macroeconomic health. --- **Original URL:** https://stockmark.it/uk-budget-light-on-life-sciences-but-more-doors-open-for-biotech-start/ *Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*